Strides Pharma Science Limited Cash Flow Conversion Efficiency
Strides Pharma Science Limited cash flow conversion efficiency. Based on the latest financial reports, Strides Pharma Science Limited (STAR) has a cash flow conversion efficiency ratio of 0.140x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs3.91 Billion ≈ $42.34 Million USD) by net assets (Rs28.03 Billion ≈ $303.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Strides Pharma Science Limited (2005–2026)
Cash flow conversion efficiency of Strides Pharma Science Limited from 2005 to 2026. This chart illustrates how Strides Pharma Science Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Strides Pharma Science Limited (STAR) share price today for real-time trading data and today's change.
Strides Pharma Science Limited Cash Flow Conversion Ratio Explained
Strides Pharma Science Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Strides Pharma Science Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Strides Pharma Science Limited ranked by their cash flow conversion efficiency. Also see STAR market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avia Avian PT Tbk
JK:AVIA
|
0.062x |
|
Suzhou GYZ Electronic Technology Co. Ltd. A
SHG:688260
|
0.057x |
|
Sri Trang Agro-Industry Public Company Limited
BK:STA
|
-0.079x |
|
Artivion Inc
NYSE:AORT
|
-0.003x |
|
China Reinsurance (Group) Corporation
F:C53
|
0.064x |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
0.032x |
|
Pet Valu Holdings Ltd
TO:PET
|
0.518x |
|
Huizhou China Eagle Electronic Technology Co Ltd
SHE:002579
|
0.090x |
Annual Cash Flow Conversion Efficiency for Strides Pharma Science Limited (2005–2026)
The table below shows the annual cash flow conversion efficiency of Strides Pharma Science Limited from 2005 to 2026. Review Strides Pharma Science Limited (STAR) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs31.49 Billion ≈ $340.59 Million |
Rs5.39 Billion ≈ $58.31 Million |
0.171x | -35.30% |
| 2025-03-31 | Rs25.86 Billion ≈ $279.72 Million |
Rs6.84 Billion ≈ $74.01 Million |
0.265x | -21.81% |
| 2024-03-31 | Rs20.72 Billion ≈ $224.05 Million |
Rs7.01 Billion ≈ $75.82 Million |
0.338x | +1555.68% |
| 2023-03-31 | Rs21.73 Billion ≈ $234.99 Million |
Rs444.11 Million ≈ $4.80 Million |
0.020x | +118.89% |
| 2022-03-31 | Rs23.83 Billion ≈ $257.75 Million |
Rs-2.58 Billion ≈ $-27.88 Million |
-0.108x | -163.23% |
| 2021-03-31 | Rs28.14 Billion ≈ $304.32 Million |
Rs4.81 Billion ≈ $52.07 Million |
0.171x | +116.77% |
| 2020-03-31 | Rs25.95 Billion ≈ $280.60 Million |
Rs2.05 Billion ≈ $22.15 Million |
0.079x | +268.20% |
| 2019-03-31 | Rs28.02 Billion ≈ $302.99 Million |
Rs600.55 Million ≈ $6.49 Million |
0.021x | -70.10% |
| 2018-03-31 | Rs26.09 Billion ≈ $282.18 Million |
Rs1.87 Billion ≈ $20.23 Million |
0.072x | -28.48% |
| 2017-03-31 | Rs28.74 Billion ≈ $310.86 Million |
Rs2.88 Billion ≈ $31.16 Million |
0.100x | +306.53% |
| 2016-03-31 | Rs29.06 Billion ≈ $314.27 Million |
Rs716.57 Million ≈ $7.75 Million |
0.025x | -65.60% |
| 2015-03-31 | Rs11.64 Billion ≈ $125.84 Million |
Rs834.00 Million ≈ $9.02 Million |
0.072x | +135.70% |
| 2014-03-31 | Rs10.82 Billion ≈ $117.07 Million |
Rs-2.17 Billion ≈ $-23.51 Million |
-0.201x | -413.53% |
| 2013-03-31 | Rs20.98 Billion ≈ $226.90 Million |
Rs1.34 Billion ≈ $14.53 Million |
0.064x | -80.13% |
| 2012-03-31 | Rs14.18 Billion ≈ $153.34 Million |
Rs4.57 Billion ≈ $49.43 Million |
0.322x | +54.77% |
| 2011-03-31 | Rs15.55 Billion ≈ $168.20 Million |
Rs3.24 Billion ≈ $35.03 Million |
0.208x | +255.34% |
| 2010-03-31 | Rs10.90 Billion ≈ $117.83 Million |
Rs638.65 Million ≈ $6.91 Million |
0.059x | -70.36% |
| 2009-03-31 | Rs5.96 Billion ≈ $64.42 Million |
Rs1.18 Billion ≈ $12.74 Million |
0.198x | -41.18% |
| 2008-03-31 | Rs2.94 Billion ≈ $31.74 Million |
Rs987.01 Million ≈ $10.67 Million |
0.336x | +34.31% |
| 2007-03-31 | Rs4.31 Billion ≈ $46.59 Million |
Rs1.08 Billion ≈ $11.66 Million |
0.250x | +9.80% |
| 2006-03-31 | Rs3.47 Billion ≈ $37.48 Million |
Rs790.26 Million ≈ $8.55 Million |
0.228x | -33.74% |
| 2005-03-31 | Rs2.18 Billion ≈ $23.54 Million |
Rs749.22 Million ≈ $8.10 Million |
0.344x | -- |
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasalsprays, topical formulations, an… Read more